BioCryst wins FDA approval for Orladeyo oral pellets

BioCryst Pharmaceuticals (BCRX) stock gains as the FDA approves an oral pellet formulation of its Orladeyo drug for children with hereditary angioedema. Read more here.

FDA approves BioCryst's oral pellet formulation of rare disease drug for young children

The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent hereditary angioedema attacks in children aged 2 to under 12, the company ...

How to spot suspicious health supplements and avoid getting scammed

Snopes readers regularly ask whether supplement brands like Neurocept and Burn Peak are legit. Here's how you can tell yourself.